



April 8, 2026

Senate Health & Human Services Committee  
Colorado General Assembly

**Re: SB 26-130 – the Medical Spa Prescription Drug Consumer Protection Act (SUPPORT)**

Dear Chair Mullica, Vice Chair Jodeh and Committee Members:

We are writing on behalf of the Alliance for Safe Biologic Medicines (ASBM), an organization representing physicians, pharmacists, patient advocates, manufacturers and researchers committed to ensuring that patients have access to safe, effective, and properly regulated medicines.

We write to express our support for **SB 26-130, the Medical Spa Prescription Drug Consumer Protection Act**. This legislation would establish important, targeted safeguards to help protect Colorado patients receiving prescription-drug treatments in medical spa settings.

Medical spas are increasingly offering services involving prescription medicines, including injectable therapies and other treatments that require appropriate clinical oversight, safe handling, and accurate patient information. While these services may be marketed as routine or cosmetic, they involve products and procedures that can carry meaningful risks if medications are improperly sourced, stored, administered, or advertised.

SB 26-130 appropriately addresses these concerns by creating clear guardrails around the use of prescription drugs in medical spas. In particular, the bill helps ensure that medications are obtained from authorized sources, that licensed practitioners are responsible for oversight, and that patients are protected from false or misleading representations about the safety, quality, or regulatory status of the products they receive.

These are reasonable and necessary consumer protections. Patients should be able to trust that any prescription medicine administered in a medical spa is authentic, appropriately handled, and used under qualified medical supervision. They should also be able to make informed decisions based on truthful information, not marketing that obscures important differences in product quality, approval status, or risk.


At a time when the use of prescription medicines in nontraditional care settings is expanding rapidly, Colorado should ensure that patient safety standards keep pace. SB 26-130 does not restrict legitimate care; it helps ensure that such care is delivered responsibly and transparently.

For these reasons, ASBM respectfully urges you to support **SB 26-130**.


Sincerely,

*Ralph McKibbin*

Ralph McKibbin, MD FACP FACG AGAF  
Chairman



Michael Reilly, Esq.  
Executive Director, Alliance for Safe Biologic Medicines



Philip J Schneider MS FASHP FFIP  
Advisory Board Chair

**ASBM Steering Committee Members:**

Alliance for Patient Access  
American Academy of Dermatology  
Autoimmune Association  
Association of Clinical Research Organizations  
Colon Cancer Alliance  
Global Colon Cancer Association  
Global Healthy Living Foundation  
Health HIV  
International Cancer Advocacy Network  
Kidney Cancer Association  
Lupus and Allied Diseases Association, Inc.  
National Hispanic Medical Association  
National Psoriasis Foundation  
ZeroCancer